All four sources cited in the post exist, are correctly described, and are peer reviewed. This is unusually well sourced for viral science content.

The 2025 clinical trial is real and matches the post's description. A human dental pulp stem cell (DPSC) injection was developed to promote periodontal regeneration through a non-invasive procedure, and a total of 132 patients with chronic periodontitis (158 teeth) from two centers in China were included.

Thirty-six were randomly assigned to different DPSC dose groups (ranging from 1 x 10^6 to 1 x 10^7 DPSCs per tooth, with nine injected with saline only), and 96 were randomly assigned to a single-injection group. The authors themselves temper the result: larger trials are warranted to validate these findings (ClinicalTrials.gov registration: NCT05924373) . Note this trial concerns gum and bone tissue around teeth, not any of the four systemic conditions named in the claim.

For the four headline conditions, the evidence is preclinical or early stage. The 2019 review the post cites states that DPSCs are mesenchymal stem cells with multipotent differentiation and self-renewal ability, useful not only for dental diseases but also for systemic diseases, with extensive studies suggesting they are effective for various diseases such as spinal cord injuries and others . The spinal cord injury source is a review noting that recent studies have highlighted that DPSCs may contribute to anti-inflammatory regulation, anti-apoptotic regulation, and axonal regeneration in the treatment of SCI patients , building on animal work in which rats with severe spinal cord injury transplanted with human dental pulp stem cells showed marked recovery of hind limb function . That same coverage notes plainly that for spinal cord injury there is currently no proven reparative treatment .

Wisdom teeth specifically are a legitimate source. DPSCs were first isolated from adult human third molars (wisdom teeth) and represent a readily accessible and minimally invasive source of mesenchymal stem cells with distinct neurogenic potential, originating from the cranial neural crest, and wisdom teeth are particularly valuable as a DPSC source due to their frequent extraction.

Human trials for the systemic conditions named do exist but are early and largely unpublished. Clinical trials using DPSCs for systemic diseases such as diabetes (NCT03912480), knee osteoarthritis (NCT04130100), and liver cirrhosis (NCT03957655) have been conducted. A 2024 review of registries found that 14 clinical trials using dental stem cells for systemic applications have been registered and/or completed since 2018 but are yet to be published, spanning COVID-19, diabetes, antiaging, severe lung contusion, spinal cord injury, cerebral palsy, liver cirrhosis, and osteoarthritis .